

BRITISH PHARMACOPOEIA COMMISSION
EXPERT ADVISORY GROUP: MEDICINAL CHEMICALS 3

SUMMARY MINUTES

A meeting of Expert Advisory Group (EAG): Medicinal Chemicals 3 (MC3) was held virtually on Thursday 24th February 2022.

Present: Professor M Almond (*Chairman*), Mr J Beach (*vice-Chairman*), Dr K Foster, Mr P Hampshire, Dr R Torano, Mr I Williams, Mr C Goddard

In attendance: Mr A Evans, Miss H Ashraf

INTRODUCTORY REMARKS

The Chairman welcomed everyone to the meeting, the first meeting to take place virtually.

Declaration of interests Members had all provided a declaration of their interest prior to the meeting and were asked to declare any specific interests on topics prior to the commencement of discussions; these would be noted in the minutes.

MHRA Update Dr June Raine has been announced as the permanent CEO for MHRA. Members were made aware that the BP will remain working remotely and likely to remain the case for some time. It is anticipated that all EAG meetings will be held remotely for the time being.

Expenses Members were reminded that any queries with regard to expenses should be sent to Mr Brian Delahunty at the Secretariat. Attendance fees for virtual meetings were permitted at the usual rate.

I MINUTES

MC3(22)02

The minutes and summary minutes of the meeting held on 23rd September 2021 were confirmed.

II MATTERS ARISING FROM THE MINUTES

MC3(22)03

The following matters arising were noted.

- Imipramine Tablets – this was signed off for BP2023
- Betamethasone and Neomycin Preparations – there was a discussion around the impurities sections which the secretariat will look into further
- Diazepam Preparations – Mr Hampshire kindly sent through a lot of information for these with some new tests.

Expert Advisory Group Medicinal Chemicals 3

- Brimonidine Eye drops – scheduled with the laboratory therefore an update will be provided in the next meeting.
- Cytarabine preparations have also been scheduled with the laboratory as well.

IV MONOGRAPHS FOR THE BP 2023+

630 Escitalopram Preparations MC3(22)04

The secretariat to make amendments to the draft monographs and publish in 2023.

631 MOMETASONE CREAM MC3(22)05

Members agreed the Secretariat to contact the MAH to gather further data for clarification.

632 SODIUM PICOSULFATE ORAL DROPS MC3(22)06

BP secretariat to publish in BP2023 after amendments from comments from members.

633 EPLERENONE TABLETS MC3(22)07

BP Secretariat to look at laboratory data and then proceed to public consultation once amendments are made.

634 FLUTICASONE PREPARATIONS MC3(22)08

No action for BP secretariat.

635 TRIAMCINOLONE OINTMENT MC3(22)09

No action for BP secretariat.

**IV MONOGRAPHS FOR BP 2024+
636 Ropinirole Preparations MC3(22)10**

Secretariat to update draft monograph and laboratory requisition to consider comments from members. Secretariat to send draft monographs to laboratory.

637 ESTRADIOL TABLETS MC3(22)11

Secretariat to make amendments to draft monographs and progress to public consultation.

V

FOR INFORMATION

638 MC3 Work Programme MC3(22)12

Expert Advisory Group Medicinal Chemicals 3

A copy of the work programme for the EAG was provided for information. Members were asked to contribute data should they have interest in any of the products.

EUROPEAN PHARMACOPOEIA

MC3(22)13

see www.pharmacopoeia.com for European matters

VII NEXT MEETING

TBC